JPWO2020132600A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132600A5 JPWO2020132600A5 JP2021535670A JP2021535670A JPWO2020132600A5 JP WO2020132600 A5 JPWO2020132600 A5 JP WO2020132600A5 JP 2021535670 A JP2021535670 A JP 2021535670A JP 2021535670 A JP2021535670 A JP 2021535670A JP WO2020132600 A5 JPWO2020132600 A5 JP WO2020132600A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- months
- clazakizumab
- seq
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783136P | 2018-12-20 | 2018-12-20 | |
| US62/783,136 | 2018-12-20 | ||
| US201962855993P | 2019-06-01 | 2019-06-01 | |
| US62/855,993 | 2019-06-01 | ||
| PCT/US2019/068103 WO2020132600A1 (en) | 2018-12-20 | 2019-12-20 | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514381A JP2022514381A (ja) | 2022-02-10 |
| JPWO2020132600A5 true JPWO2020132600A5 (https=) | 2022-12-19 |
| JP2022514381A5 JP2022514381A5 (https=) | 2022-12-19 |
Family
ID=71101983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535670A Pending JP2022514381A (ja) | 2018-12-20 | 2019-12-20 | 臓器移植の慢性抗体介在性拒絶反応の処置でのクラザキズマブ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220073605A1 (https=) |
| EP (1) | EP3897718A4 (https=) |
| JP (1) | JP2022514381A (https=) |
| KR (1) | KR20210106521A (https=) |
| CN (1) | CN113194996B (https=) |
| AU (1) | AU2019404553A1 (https=) |
| BR (1) | BR112021010615A2 (https=) |
| CA (1) | CA3121934A1 (https=) |
| WO (1) | WO2020132600A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20220288202A1 (en) * | 2019-09-04 | 2022-09-15 | Cedars-Sinai Medical Center | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients |
| WO2025122579A1 (en) * | 2023-12-04 | 2025-06-12 | Cedars-Sinai Medical Center | Cadherin 6 expression status in determination of renal fibrosis and related uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| HUE032563T2 (en) * | 2007-05-21 | 2017-09-28 | Alderbio Holdings Llc | Antibodies to IL-6 and their use |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| EP2834368A2 (en) * | 2012-04-04 | 2015-02-11 | Assistance Publique - Hopitaux De Paris | Endothelial cells activation biomarkers characterizing antibody mediated rejection and uses thereof |
| JP6636803B2 (ja) * | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| NZ719724A (en) * | 2013-11-22 | 2022-08-26 | Takeda Pharmaceuticals Co | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| US11065319B2 (en) * | 2014-02-04 | 2021-07-20 | 3Dt Holdings, Llc | Methods for diagnosing and reducing incidences of cardiac allograft rejection |
| US20170022280A1 (en) * | 2015-07-24 | 2017-01-26 | Cedars-Sinai Medical Center | Method for treating antibody-mediated rejection post-transplantation |
| CN111867627A (zh) * | 2018-01-04 | 2020-10-30 | 维塔里斯股份有限公司 | 抗IL-6抗体例如克拉扎珠单抗(Clazakizumab)用于使实体器官移植接受者脱敏和/或用于预防、稳定或减轻抗体介导的排斥(ABMR)的用途 |
| JP2022512937A (ja) * | 2018-11-08 | 2022-02-07 | セダーズ－シナイ メディカル センター | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
-
2019
- 2019-12-20 US US17/415,993 patent/US20220073605A1/en not_active Abandoned
- 2019-12-20 KR KR1020217022866A patent/KR20210106521A/ko active Pending
- 2019-12-20 JP JP2021535670A patent/JP2022514381A/ja active Pending
- 2019-12-20 CN CN201980084166.7A patent/CN113194996B/zh active Active
- 2019-12-20 EP EP19900083.7A patent/EP3897718A4/en active Pending
- 2019-12-20 AU AU2019404553A patent/AU2019404553A1/en active Pending
- 2019-12-20 CA CA3121934A patent/CA3121934A1/en active Pending
- 2019-12-20 BR BR112021010615A patent/BR112021010615A2/pt unknown
- 2019-12-20 WO PCT/US2019/068103 patent/WO2020132600A1/en not_active Ceased
-
2025
- 2025-03-17 US US19/081,867 patent/US20250263480A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210187054A1 (en) | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kidney transplant | |
| AU2022215307B2 (en) | Methods of treating autoimmune and alloimmune disorders | |
| TWI848905B (zh) | 用於治療補體介導之疾病及病症之方法 | |
| JP2020536097A5 (https=) | ||
| US20230357433A1 (en) | Inflammatory cytokines and fatigue in subject with a complement mediated disease | |
| JP2020525411A (ja) | 肝細胞癌のための免疫療法 | |
| JP2022530533A (ja) | Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 | |
| JP7458790B2 (ja) | Ｉｌ－６阻害剤を含有する喘息の治療剤 | |
| BR112020013531A2 (pt) | Uso de anticorpo anti-il-6, por exemplo, clazakizumab para dessensibilização de receptores de transplante de órgãos sólidos e/ou para prevenir, estabilizar ou reduzir rejeição mediada por anticorpos (abmr) | |
| BR112020021721A2 (pt) | tratamento da dermatite atópica | |
| CN112424226A (zh) | 用于治疗重度哮喘的抗cd6抗体 | |
| JP2024521638A (ja) | 好酸球トラップの阻害 | |
| US12180274B2 (en) | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity | |
| BR112021007633A2 (pt) | Uso de clazakizumabe para dessensibilizar e melhorar o transplante renal em pacientes sensibilizados por hla | |
| JP2020517605A (ja) | 腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗ｃ５抗体の有効性 | |
| JPWO2020132600A5 (https=) | ||
| PT1737490E (pt) | Processos de tratamento da aterosclerose | |
| US20230035183A1 (en) | Antibodies for the treatment of chronic graft versus host disease | |
| US11459382B2 (en) | Dosage and administration of anti-C5 antibodies for treatment of protein-losing enteropathy in patients | |
| JPWO2020097566A5 (https=) | ||
| CN114728060A (zh) | 使用白介素-17（il-17）拮抗剂治疗狼疮性肾炎的方法 | |
| CN113924099A (zh) | 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性 | |
| KR102628314B1 (ko) | 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체 | |
| Sonmez et al. | Effects of antithymocyte globulin, basiliximab, and induction-free treatment in living donor kidney transplant recipients on tacrolimus-based immunosuppression | |
| JP2024517796A (ja) | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 |